AmerisourceBergen Corporation (ABC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AmerisourceBergen Corporation (ABC) trades at $179.98 with AI Score 45/100 (Grade C). AmerisourceBergen Corporation is a leading pharmaceutical sourcing and distribution company, operating in the United States and internationally. Market cap: $36.15B, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for ABC: ABC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ABC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ABC: the 1 perspectives are evenly split.
AmerisourceBergen Corporation (ABC) Healthcare & Pipeline Overview
AmerisourceBergen Corporation is a global pharmaceutical distributor providing brand-name and generic drugs, healthcare products, and related services. With a focus on pharmaceutical distribution and integrated manufacturer services, the company serves a diverse customer base, including hospitals, pharmacies, and veterinary practices, navigating a complex regulatory landscape.
What Is the Investment Thesis for ABC?
AmerisourceBergen presents a stable investment opportunity within the healthcare sector, driven by its essential role in pharmaceutical distribution. The company's consistent revenue stream is supported by long-term contracts and a diversified customer base. A key value driver is the increasing demand for specialty pharmaceuticals and related services, where AmerisourceBergen has established a strong presence. However, investors may want to evaluate the relatively low profit margin of 0.5% and the potential impact of regulatory changes on drug pricing and distribution. The company's beta of 0.56 suggests lower volatility compared to the overall market. The dividend yield of 0.66% provides a modest income stream.
Based on FMP financials and quantitative analysis
ABC Key Highlights
- Market capitalization of $36.15 billion, reflecting its significant presence in the pharmaceutical distribution market.
- P/E ratio of 41.82, indicating investor expectations for future earnings growth.
- Gross margin of 3.3%, highlighting the competitive pricing environment in the pharmaceutical distribution industry.
- Dividend yield of 0.66%, providing a modest return for investors.
- Beta of 0.56, suggesting lower volatility compared to the broader market.
Who Are ABC's Competitors?
ABC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BDX Becton, Dickinson and Company | $147.12 | +0.94% | $53.30B | 51 |
| CAKFY McKesson Europe AG | $4.10 | +0.00% | $5.37B | 35 |
| CVET Covetrus, Inc. | $20.99 | +0.00% | 45 | |
| FCAMX Franklin California High Yield Municipal Fund Class A1 | $9.73 | +0.00% | $3.29B | 51 |
| FCTKX Fidelity Freedom 2055 K6 | $20.05 | +0.55% | $16.91B | 47 |
| JEMSX JPMorgan Emerging Markets Equity Fund | $51.23 | +1.33% | $10.12B | 47 |
| FID First Trust S&P International Dividend Aristocrats ETF | $22.04 | +0.11% | $165.57M | 47 |
| PFDOX PFG PIMCO Active Core Bond Strategy R | $8.61 | -0.12% | $174.67M | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ABC's Key Strengths?
- Extensive distribution network
- Strong relationships with pharmaceutical manufacturers
- Comprehensive service offerings
- Scale and purchasing power
What Are ABC's Weaknesses?
- Low profit margin
- Dependence on pharmaceutical manufacturers
- Exposure to regulatory changes
- High debt levels
What Could Drive ABC Stock Higher?
- Increasing demand for specialty pharmaceuticals, driving growth in related services.
- Strategic partnerships with pharmaceutical manufacturers to enhance product access and distribution.
- Potential acquisitions of complementary businesses to expand service offerings and geographic reach.
- Investments in technology and infrastructure to improve supply chain efficiency.
What Are the Key Risks for ABC?
- Increased competition from other pharmaceutical distributors and manufacturers.
- Drug pricing pressures and regulatory changes impacting reimbursement rates.
- Economic downturn affecting demand for healthcare products and services.
- Dependence on key pharmaceutical manufacturers for product supply.
What Are the Growth Opportunities for ABC?
- Expansion of Specialty Pharmaceutical Services: The increasing demand for specialty pharmaceuticals, particularly in oncology and immunology, presents a significant growth opportunity for AmerisourceBergen. By expanding its services for specialty drug manufacturers and providers, including data analytics and patient support programs, the company can capture a larger share of this high-growth market. The specialty pharmaceutical market is projected to reach $400 billion by 2026, offering substantial revenue potential.
- Strategic Acquisitions and Partnerships: AmerisourceBergen can pursue strategic acquisitions and partnerships to expand its service offerings and geographic reach. Acquiring companies with complementary capabilities, such as specialty pharmacies or healthcare technology providers, can enhance its competitive position and drive revenue growth. Partnerships with pharmaceutical manufacturers can also strengthen its supply chain and improve access to innovative therapies. These initiatives can be implemented within the next 1-3 years.
- Growth in Animal Health Market: The animal health market is experiencing steady growth, driven by increasing pet ownership and rising demand for animal healthcare products. AmerisourceBergen's Other segment, which includes animal health products and services, can capitalize on this trend by expanding its product portfolio and distribution network. The global animal health market is expected to reach $75 billion by 2028, providing a significant growth opportunity.
- Enhancement of Supply Chain Efficiency: Improving supply chain efficiency can reduce costs and enhance customer satisfaction. AmerisourceBergen can invest in technology and infrastructure to optimize its distribution network, improve inventory management, and streamline order processing. By leveraging data analytics and automation, the company can identify and address inefficiencies in the supply chain, leading to improved profitability and competitiveness. This is an ongoing opportunity.
- Expansion of Integrated Manufacturer Services: The demand for integrated manufacturer services, such as clinical trial support and product commercialization, is growing as pharmaceutical companies seek to outsource non-core activities. AmerisourceBergen can expand its service offerings in this area to capture a larger share of the market. By providing comprehensive solutions that support the entire product lifecycle, the company can become a strategic partner for pharmaceutical manufacturers and drive long-term revenue growth. This expansion can occur over the next 2-5 years.
What Opportunities Does ABC Have?
- Expansion of specialty pharmaceutical services
- Strategic acquisitions and partnerships
- Growth in animal health market
- Enhancement of supply chain efficiency
What Threats Does ABC Face?
- Increased competition
- Drug pricing pressures
- Regulatory changes
- Economic downturn
What Are ABC's Competitive Advantages?
- Extensive distribution network: AmerisourceBergen has a well-established distribution network that reaches a wide range of healthcare providers.
- Strong relationships with pharmaceutical manufacturers: The company has long-standing relationships with major pharmaceutical manufacturers, ensuring access to a wide range of products.
- Comprehensive service offerings: AmerisourceBergen offers a comprehensive suite of services, including pharmaceutical distribution, pharmacy management, and integrated manufacturer services.
- Scale and purchasing power: The company's scale and purchasing power allow it to negotiate favorable pricing with manufacturers and achieve economies of scale.
What Does ABC Do?
AmerisourceBergen Corporation, established in 2001 and headquartered in Conshohocken, Pennsylvania, is a leading global healthcare solutions provider focused on pharmaceutical distribution and related services. The company operates through two primary segments: Pharmaceutical Distribution and Other. The Pharmaceutical Distribution segment distributes a wide range of pharmaceutical products, including brand-name and generic drugs, over-the-counter healthcare products, and home healthcare supplies. This segment serves various healthcare providers, such as acute care hospitals, retail pharmacies, mail-order pharmacies, medical clinics, and long-term care facilities. AmerisourceBergen also offers pharmacy management, staffing, and consulting services, along with supply management software and packaging solutions. The Other segment provides integrated manufacturer services, including clinical trial support, product post-approval services, and commercialization support. Additionally, this segment offers specialty transportation and logistics services for the biopharmaceutical industry and distributes pharmaceuticals, vaccines, and other products to the companion and production animal markets. AmerisourceBergen's extensive distribution network and comprehensive service offerings position it as a key player in the pharmaceutical supply chain, connecting manufacturers and healthcare providers to improve patient access to medications and healthcare solutions.
What Products and Services Does ABC Offer?
- Distributes brand-name and generic pharmaceuticals to healthcare providers.
- Provides over-the-counter healthcare products and home healthcare supplies.
- Offers pharmacy management, staffing, and consulting services.
- Develops and implements supply management software for healthcare providers.
- Provides packaging solutions to institutional and retail healthcare providers.
- Distributes plasma and other blood products, injectable pharmaceuticals, and vaccines.
- Offers data analytics and outcomes research for biotechnology and pharmaceutical manufacturers.
- Provides integrated manufacturer services, including clinical trial support and product commercialization.
How Does ABC Make Money?
- Generates revenue through the distribution of pharmaceutical products to healthcare providers.
- Provides value-added services, such as pharmacy management and consulting, to generate additional revenue.
- Offers integrated manufacturer services to pharmaceutical companies, creating a diversified revenue stream.
What Industry Does ABC Operate In?
AmerisourceBergen operates within the medical distribution industry, a sector characterized by consolidation and increasing regulatory scrutiny. The industry is driven by the growing demand for pharmaceuticals, driven by an aging population and advancements in medical treatments. Key trends include the rise of specialty pharmaceuticals, the increasing importance of supply chain efficiency, and the growing focus on patient outcomes. AmerisourceBergen competes with other major distributors and faces pressure from manufacturers seeking to control distribution channels. The industry is subject to regulations related to drug pricing, safety, and distribution practices.
Who Are ABC's Key Customers?
- Acute care hospitals and health systems
- Independent and chain retail pharmacies
- Mail order pharmacies
- Medical clinics
- Long-term care and alternate site pharmacies
ABC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $85.93B | $560M | $2.87 |
| Q3 2025 | $83.73B | -$340M | $-1.75 |
| Q2 2025 | $80.66B | $687M | $3.52 |
| Q1 2025 | $75.45B | $718M | $3.68 |
Based on FMP financials and quantitative analysis
ABC Latest News
-
The FCC is reviewing Disney's ABC broadcast licenses, citing its probe into the company's DEI policies
businessinsider.com · Apr 28, 2026
-
FCC to order early license reviews of Disney-owned ABC stations, source says
reuters.com · Apr 28, 2026
-
FCC's Brendan Carr Planning Early Review of Disney's ABC TV Licenses
wsj.com · Apr 28, 2026
-
How many ABC News staffers will get axed in Disney bloodbath?
nypost.com · Apr 14, 2026
ABC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABC.
Price Targets
Wall Street price target analysis for ABC.
ABC MoonshotScore
What does this score mean?
The MoonshotScore rates ABC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
The FCC is reviewing Disney's ABC broadcast licenses, citing its probe into the company's DEI policies
FCC to order early license reviews of Disney-owned ABC stations, source says
FCC's Brendan Carr Planning Early Review of Disney's ABC TV Licenses
How many ABC News staffers will get axed in Disney bloodbath?
Leadership: Steven H. Collis
Chairman, President and Chief Executive Officer
Steven H. Collis has served as Chairman, President & CEO of AmerisourceBergen since 2011. Prior to this, he held various leadership positions within the company, including President and Chief Operating Officer. His extensive experience in the pharmaceutical industry spans over two decades, providing him with a deep understanding of the market dynamics and challenges. He is known for his strategic vision and focus on innovation.
Track Record: Under Steven H. Collis's leadership, AmerisourceBergen has experienced significant growth and expansion, solidifying its position as a leading global healthcare solutions provider. He has overseen key acquisitions and strategic initiatives that have enhanced the company's service offerings and geographic reach. Collis has also been instrumental in driving innovation and improving operational efficiency, contributing to the company's financial performance.
ABC Healthcare Stock FAQ
What does AmerisourceBergen Corporation do?
AmerisourceBergen Corporation is a leading global pharmaceutical distributor that sources and distributes pharmaceutical products to healthcare providers, including hospitals, pharmacies, and clinics. The company also provides a range of services, such as pharmacy management, staffing, and consulting, as well as integrated manufacturer services, including clinical trial support and product commercialization. AmerisourceBergen plays a critical role in the pharmaceutical supply chain, connecting manufacturers and healthcare providers to ensure patients have access to the medications they need.
What do analysts say about ABC stock?
Analyst consensus for AmerisourceBergen Corporation (ABC) is generally positive, reflecting the company's stable position in the pharmaceutical distribution market. Key valuation metrics, such as the P/E ratio of 41.82, suggest investor expectations for future earnings growth. Analysts are closely monitoring the company's ability to manage drug pricing pressures and regulatory changes, as well as its success in expanding its specialty pharmaceutical services. Growth considerations include the increasing demand for specialty drugs and the company's strategic initiatives to enhance supply chain efficiency.
What are the main risks for ABC?
The main risks for AmerisourceBergen Corporation include increased competition from other pharmaceutical distributors and manufacturers, which could put pressure on pricing and margins. Drug pricing pressures and regulatory changes, such as potential changes to reimbursement rates, also pose a significant risk. An economic downturn could affect demand for healthcare products and services, impacting revenue growth. Additionally, the company is dependent on key pharmaceutical manufacturers for product supply, and any disruption in these relationships could negatively affect its business.
How does AmerisourceBergen Corporation manage patent expiration risks?
AmerisourceBergen manages patent expiration risks by diversifying its product portfolio and focusing on generic pharmaceuticals. As patents for brand-name drugs expire, the company can distribute generic versions, mitigating the impact of lost sales from the original drugs. AmerisourceBergen also works closely with pharmaceutical manufacturers to anticipate patent expirations and develop strategies to manage the transition to generic alternatives. This includes securing supply agreements and optimizing distribution channels to capitalize on the demand for lower-cost generic medications.
How does AmerisourceBergen Corporation navigate regulatory approval processes?
AmerisourceBergen navigates regulatory approval processes by maintaining a strong compliance program and working closely with regulatory agencies. The company ensures that its distribution practices meet all applicable regulations and standards, including those related to drug safety and security. AmerisourceBergen also monitors regulatory developments and adapts its processes to comply with new requirements. By maintaining a proactive approach to regulatory compliance, the company minimizes the risk of disruptions to its operations and maintains its reputation as a trusted distributor of pharmaceutical products.
What are the key factors to evaluate for ABC?
AmerisourceBergen Corporation (ABC) holds an AI score of 45/100 (low). Not financial advice.
How frequently does ABC data refresh on this page?
ABC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ABC's recent stock price performance?
AmerisourceBergen Corporation (ABC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive distribution network. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.